Ana Kober Leite

Dr. Ana Kober Leite

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2017 in International Journal of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
BCBeatriz Godoi Cavalheiro
Beatriz Godoi Cavalheiro
ALAna Kober Leite
Ana Kober Leite
LMLeandro Luongo Matos
Leandro Luongo Matos
AMAline Palermo Miazaki
Aline Palermo Miazaki
JIJan Marcel Ientile
Jan Marcel Ientile
CCClaudio Roberto Cernea
Claudio Roberto Cernea
Background: Thyroid fine needle aspiration (FNA) has a well-established role in the diagnosis of thyroid nodules, and the “Bethesda system for reporting thyroid cytopathology” is used to interpret FNA results. Bethesda categories III and IV encompass varying risks of malignancy. In addition, there is some debate in the literature about how to select among many acceptable treatment approaches. Objectives: To establish an association between these 2 cytological categories and malignancy rates in patients treated in a referral tertiary cancer center, where surgical treatment is recommended for all these patients. Methods: A total of 615 thyroid nodules (582 patients) were included in this retrospective study. There were 478 nodules that were classified as Bethesda category III and 137 nodules as Bethesda category IV. Electronic records were reviewed to establish a correlation between the FNA cytological results and the final histopathological analyses. Incidentally detected carcinomas were considered separately. Results: Among the bethesda category III group, 75 malignant nodules (15.7%) were coincident with the target nodule (74 patients, 16.2%). Incidental carcinomas were found in 13.8% of these patients. The remaining 403 (84.3%) target nodules were benign. Among the bethesda category IV nodules, 23 malignant nodules (16.8%) were coincident with the target nodule. Incidental carcinomas were found in 25 patients (19.7%). The other 114 target nodules were benign. A total of 46 patients (52.3%) had carcinomas in the thyroid lobe contralateral to the one containing the target nodule, and 40 patients (45.5%) had carcinomas exclusively in the contralateral lobe. Conclusions: We observed a 16% rate of malignancy in nodules classified as bethesda category III and 17% among bethesda category IV. When incidental carcinomas were included, the rates of malignancy doubled. Keywords: Needle Biopsy; Thyroid Cytology; Thyroid Neoplasms; Thyroid Nodule; Thyroidectomy; Incidental Findings

1 June 2017 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
ALAna Kober Leite
Ana Kober Leite
BCBeatriz G. Cavalheiro
Beatriz G. Cavalheiro
MKMarco Aurélio Kulcsar
Marco Aurélio Kulcsar
AHAna de Oliveira Hoff
Ana de Oliveira Hoff
LBLenine G. Brandão
Lenine G. Brandão
LMLeandro Luongo Matos
Leandro Luongo Matos
Key words: Thyroid; thyroid cancer; metastasis; prognosis; death

1 June 2021 in Head & Neck
Verified
Journal Article
Closed access
PDF file
BCBeatriz G. Cavalheiro
Beatriz G. Cavalheiro
LMLeandro Luongo Matos
Leandro Luongo Matos
ALAna Kober Leite
Ana Kober Leite
MKMarco Aurelio Vamondes Kulcsar
Marco Aurelio Vamondes Kulcsar
CCClaudio Roberto Cernea
Claudio Roberto Cernea
Luiz P. KowalskiLuiz P. Kowalski
Luiz P. Kowalski

1 January 2017 in Endocrine Practice
Verified
Journal Article
Closed access
ALAna Kober Leite
Ana Kober Leite
MKMarco Aurélio Vamondes Kulcsar
Marco Aurélio Vamondes Kulcsar
BCBeatriz de Godoi Cavalheiro
Beatriz de Godoi Cavalheiro
EMEvandro Sobroza de Mello
Evandro Sobroza de Mello
VAVenâncio Avancini F. Alves
Venâncio Avancini F. Alves
LMLeandro Luongo Matos
Leandro Luongo Matos

19 October 2021 in Endocrine
Verified
Journal Article
Closed access
PDF file
KNKamilla Schmitz Nunes
Kamilla Schmitz Nunes
LMLeandro Luongo Matos
Leandro Luongo Matos
BCBeatriz G. Cavalheiro
Beatriz G. Cavalheiro
FMFelipe Ferraz Magnabosco
Felipe Ferraz Magnabosco
MTMarcos Roberto Tavares
Marcos Roberto Tavares
ALAna Kober Leite
Ana Kober Leite

1 April 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
LMLeandro Luongo Matos
Leandro Luongo Matos
Luiz P. KowalskiLuiz P. Kowalski
Luiz P. Kowalski
ACAline Lauda Freitas Chaves
Aline Lauda Freitas Chaves
Thiago OliveiraThiago Oliveira
Thiago Oliveira
GMGustavo Marta
Gustavo Marta
HCHEADSpAcE Consortium
HEADSpAcE Consortium
Head and neck squamous cell carcinoma (HNSCC) is well known as a serious health problem worldwide, especially in low-income countries or those with limited resources, such as most countries in Latin America. International guidelines cannot always be applied to a population from a large region with specific conditions. This study established a Latin American guideline for care of patients with head and neck cancer and presented evidence of HNSCC management considering availability and oncologic benefit. A panel composed of 41 head and neck cancer experts systematically worked according to a modified Delphi process on (1) document compilation of evidence-based answers to different questions contextualized by resource availability and oncologic benefit regarding Latin America (region of limited resources and/or without access to all necessary health care system infrastructure), (2) revision of the answers and the classification of levels of evidence and degrees of recommendations of all recommendations, (3) validation of the consensus through two rounds of online surveys, and (4) manuscript composition. The consensus consists of 12 sections: Head and neck cancer staging, Histopathologic evaluation of head and neck cancer, Head and neck surgery—oral cavity, Clinical oncology—oral cavity, Head and neck surgery—oropharynx, Clinical oncology—oropharynx, Head and neck surgery—larynx, Head and neck surgery—larynx/hypopharynx, Clinical oncology—larynx/hypopharynx, Clinical oncology—recurrent and metastatic head and neck cancer, Head and neck surgery—reconstruction and rehabilitation, and Radiation therapy. The present consensus established 48 recommendations on HNSCC patient care considering the availability of resources and focusing on oncologic benefit. These recommendations could also be used to formulate strategies in other regions like Latin America countries.